Soleno Therapeutics market cap is $66.3 m.

Soleno Therapeutics Net income (Q1, 2021)-9 M

Soleno Therapeutics EBIT (Q1, 2021)-9.2 M

Soleno Therapeutics Cash, 31-Mar-202141.6 M

Soleno Therapeutics EV24.7 M

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|

## Revenue | 607.5k | 1.5m | |||||

## Cost of goods sold | 352.7k | 1.5m | |||||

## Gross profit | 254.8k | (58.5k) | |||||

| 42% | (4%) | |||||

## Sales and marketing expense | 252.4k | 1.7m | 1.6m | 25.7k | |||

## R&D expense | 2.2m | 4.5m | 5.2m | 3.1m | 7.2m | 16.3m | 23.2m |

## General and administrative expense | 2.7m | 6.1m | 6.7m | 6.6m | 6.6m | 6.9m | 8.8m |

## Operating expense total | 5.2m | 12.4m | 13.6m | 9.7m | 13.7m | 23.2m | 31.9m |

## EBIT | (5.2m) | (12.2m) | (13.6m) | (12.2m) | (14.3m) | (23.5m) | (36.3m) |

| (2002%) | (938%) | |||||

## Interest expense | 2.5m | ||||||

## Interest income | 1.1k | ||||||

## Investment income | (478.0k) | ||||||

## Pre tax profit | (12.0m) | 13.7m | (11.8m) | (30.8m) | (24.6m) | ||

## Income tax expense | 21.7k | (1.7m) | |||||

## Net Income | (13.9m) | (15.9m) | (15.7m) | (15.7m) | (13.3m) | (30.8m) | (24.6m) |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|

## Cash | 8.0m | 5.5m | 2.7m | 17.1m | 23.1m | 20.7m | 49.2m |

## Accounts Receivable | 156.1k | 133.3k | |||||

## Prepaid Expenses | 252.3k | 167.6k | 342.9k | 529.0k | 411.0k | 1.0m | |

## Inventories | 109.3k | 551.0k | 660.4k | ||||

## Current Assets | 8.3m | 6.4m | 3.8m | 18.0m | 24.7m | 21.1m | 50.2m |

## PP&E | 57.6k | 85.7k | 102.6k | 22.9k | 12.0k | 22.0k | 19.0k |

## Goodwill | 916.8k | 718.0k | |||||

## Total Assets | 8.4m | 8.2m | 5.6m | 39.0m | 43.2m | 38.2m | 65.0m |

## Accounts Payable | 986.8k | 695.1k | 537.9k | 633.1k | 934.0k | 2.0m | 3.5m |

## Short-term debt | 101.5k | 305.0k | 139.0k | ||||

## Current Liabilities | 1.3m | 3.2m | 1.7m | 1.7m | 1.9m | 5.0m | 8.6m |

## Long-term debt | 139.0k | ||||||

## Total Debt | 101.5k | 305.0k | 278.0k | ||||

## Total Liabilities | 2.1m | 12.5m | 12.7m | 23.2m | 19.4m | ||

## Common Stock | 6.8k | 14.0k | 19.2k | 32.0k | 45.0k | 80.0k | |

## Additional Paid-in Capital | 60.6m | 89.5m | 101.7m | 140.5m | 157.4m | 172.7m | 227.9m |

## Retained Earnings | (71.0m) | (86.2m) | (98.3m) | (114.0m) | (127.0m) | (157.8m) | (182.4m) |

## Total Equity | (10.3m) | 3.2m | 3.4m | 26.5m | 30.4m | 14.9m | 45.5m |

## Financial Leverage | -0.8 x | 2.5 x | 1.6 x | 1.5 x | 1.4 x | 2.6 x | 1.4 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|

## Net Income | (13.9m) | (15.9m) | (15.7m) | (13.3m) | (30.8m) | (24.6m) | |

## Depreciation and Amortization | 28.5k | 108.2k | 131.6k | 1.6m | 2.0m | 2.0m | 2.0m |

## Accounts Receivable | 149.6k | (156.1k) | 22.8k | ||||

## Inventories | (109.3k) | (441.7k) | (109.4k) | ||||

## Accounts Payable | 353.9k | 211.9k | (149.2k) | 190.6k | 249.0k | 1.1m | 1.5m |

## Cash From Operating Activities | (4.5m) | (10.3m) | (13.5m) | (9.9m) | (11.7m) | (17.4m) | (25.2m) |

## Purchases of PP&E | (30.7k) | (55.8k) | (38.7k) | (2.6k) | (8.0k) | (21.0k) | (7.0k) |

## Cash From Investing Activities | (30.7k) | (1.3m) | (38.7k) | 378.8k | (180.0k) | 528.0k | (7.0k) |

## Short-term Borrowings | (101.5k) | ||||||

## Long-term Borrowings | (2.0k) | (17.0k) | |||||

## Cash From Financing Activities | 11.2m | 9.2m | 10.8m | 23.9m | 17.8m | 14.5m | 53.7m |

## Net Change in Cash | 6.7m | (2.5m) | (2.8m) | 14.4m | 6.0m | (2.4m) | 28.5m |

## Income Taxes Paid | 800.0 |

USD | Q3, 2014 |
---|